| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
Cutaneous angiosarcoma is a malignant skin tumor with a high mortality rate despite the currently available therapeutic protocols.
Inactivated, replication-defective Sendai virus particles(HVJ-E) have been shown to have a powerful anti-tumor effect.
We aimed to establish a novel therapeutic tool for anigiosarcoma with HVJ-E, IL-2 gene, and/or sunitinib.
HVJ-E significantly inhibited tumor growth of angiosarcoma in vivo.
HVJ-E-containing murine IL-2 gene resulted in an even more significant inhibition of tumor growth than HVJ-E alone.
Anti-tumor effects of HVJ-E were associated with an increase of CD8(+) cells and NK cells, and a decrease of Tregs.
Sunitinib inhibits cell growth of ISOS-1 cells in vitro and in vivo.
The combination of the HVJ-E and Sunitinib resulted in an even more significant inhibition of tumor growth than HVJ-E alone.
|
